Gabelli Funds LLC Has $925,000 Stock Holdings in Silk Road Medical, Inc (NASDAQ:SILK)

Gabelli Funds LLC trimmed its stake in shares of Silk Road Medical, Inc (NASDAQ:SILKFree Report) by 23.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 75,392 shares of the company’s stock after selling 23,608 shares during the quarter. Gabelli Funds LLC owned about 0.19% of Silk Road Medical worth $925,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of SILK. Armistice Capital LLC acquired a new position in Silk Road Medical during the fourth quarter valued at approximately $21,693,000. Federated Hermes Inc. acquired a new position in shares of Silk Road Medical during the 4th quarter worth $5,789,000. Algert Global LLC bought a new stake in shares of Silk Road Medical during the 3rd quarter worth $1,456,000. New York State Common Retirement Fund lifted its position in shares of Silk Road Medical by 333.5% during the 3rd quarter. New York State Common Retirement Fund now owns 67,571 shares of the company’s stock worth $1,013,000 after buying an additional 51,983 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Silk Road Medical by 33.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company’s stock valued at $2,998,000 after buying an additional 50,000 shares in the last quarter.

Silk Road Medical Trading Up 1.1 %

Shares of SILK stock opened at $21.06 on Tuesday. The stock has a 50-day moving average of $19.79 and a 200-day moving average of $16.21. The company has a current ratio of 11.05, a quick ratio of 9.62 and a debt-to-equity ratio of 0.52. The stock has a market cap of $830.61 million, a price-to-earnings ratio of -15.37 and a beta of 1.51. Silk Road Medical, Inc has a 1-year low of $6.08 and a 1-year high of $34.13.

Silk Road Medical (NASDAQ:SILKGet Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.04. Silk Road Medical had a negative net margin of 29.02% and a negative return on equity of 35.47%. The firm had revenue of $48.50 million during the quarter, compared to analyst estimates of $44.67 million. During the same quarter last year, the business earned ($0.43) EPS. The company’s revenue was up 20.9% compared to the same quarter last year. On average, equities research analysts forecast that Silk Road Medical, Inc will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on SILK. Piper Sandler boosted their target price on Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 1st. Stifel Nicolaus raised their target price on shares of Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Argus upgraded shares of Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Thursday, March 7th. Finally, JPMorgan Chase & Co. raised their price objective on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Silk Road Medical has an average rating of “Hold” and a consensus target price of $20.10.

View Our Latest Report on SILK

Silk Road Medical Company Profile

(Free Report)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.

See Also

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.